PMGC Holdings Inc. (Nasdaq: ELAB) shares rose 14.06% to $1.20 on Friday as the company advanced its engineered probiotic platform. The gain follows an announcement from its subsidiary, NorthStrive Biosciences Inc., regarding plans to initiate an independent flow cytometry study. This move aims to characterize the EL-22 candidate, designed to preserve muscle during weight loss treatments involving GLP-1 receptor agonists.

EL-22 Characterization Study

The independent study will quantify myostatin antigen expression on Lactobacillus casei. This analysis supports comparability against materials previously manufactured by MOA Life Plus Co. Ltd., enhancing product identity and manufacturing consistency for EL-22. The initiative is part of PMGC Holdings' broader focus on biopharmaceutical innovation in obesity and metabolic health.

Strategic Context

PMGC Holdings operates in Medical Aesthetics and Biopharmaceutical Innovation, with a specialization in Skin Aesthetics, Obesity, and Metabolic Health. The company's focus on engineered probiotics positions it in the biopharmaceutical space, targeting muscle preservation during weight loss. Recent developments in product characterization are crucial for meeting regulatory standards and enhancing market position.

Business Overview

PMGC Holdings is leveraging its EL-22 platform to address significant health issues. The strategic focus on innovation is intended to drive future growth and investor interest. The company's efforts to ensure manufacturing consistency and product identity are key steps in its commercialization strategy.

NorthStrive Biosciences, a wholly-owned subsidiary of PMGC Holdings Inc., has filed two new U.S. patent applications to expand its EL-22 and EL-32 intellectual property portfolio into potential human pharmaceutical applications. The filings aim to preserve lean muscle mass in human patients experiencing muscle loss from GLP-1 and obesity-related weight loss treatments. The applications have been assigned U.S. Patent Application Nos. 19/709,895 for EL-22 and 19/709,950 for EL-32.

The new patent applications represent a strategic expansion from the company's previous focus on animal health and agricultural applications into potential human-use applications. The filings are directed toward preserving lean muscle mass in patients suffering from sarcopenia, obesity-related weight loss treatment, malnutrition, neurogenic atrophy, or physical inactivity. Both applications specifically address obesity-related weight loss treatments, including GLP-1 receptor agonists, as well as dual and triple agonist therapies targeting GLP-1, GIP, and/or glucagon pathways.

Patent Application Details

New Human-Use Patent Claims

The newly filed applications include claims directed to the potential use of EL-22 and EL-32 to preserve lean muscle mass in patients undergoing obesity-related weight loss treatment. The claims cover various pharmaceutical product approaches and delivery methods.

• Human-use applications for preserving lean muscle mass in patients experiencing muscle loss from sarcopenia, obesity-related weight loss treatment, malnutrition, neurogenic atrophy, or physical inactivity.
• Use in patients undergoing obesity-related weight loss treatment, including GLP-1 receptor agonists, dual agonists targeting GLP-1, GIP, and/or glucagon pathways, and triple agonists targeting GLP-1, GIP, and glucagon pathways.
• EL-22 pharmaceutical product approaches involving isolated Myo-2 peptide, Myo-2 peptide multimers, and fusion proteins involving myostatin mature protein fused to Myo-2 peptide or Myo-2 peptide multimers.
• EL-32 pharmaceutical product approaches involving a microorganism transformed with a cell surface display vector linked to genes encoding myostatin and activin A proteins.
• EL-32 microorganism embodiments involving lactic acid bacteria, including Lactobacillus paracasei.
• Combination and co-administration approaches, including taking EL-22 or EL-32 together with apelin or ursolic acid, compounds associated with muscle support.
• Multiple pharmaceutically acceptable delivery forms, including oral, injectable, nasal, topical, and other delivery formats.

Expansion of the EL-22 and EL-32 IP Portfolio

The EL-22 application includes claims directed to pharmaceutical product approaches involving myostatin-derived Myo-2 peptide constructs for potential use in preserving lean muscle mass in humans. The filing includes claims directed to an isolated Myo-2 peptide, Myo-2 peptide multimers, a fusion protein of myostatin mature protein fused to a Myo-2 peptide, and a fusion protein of myostatin mature protein fused to a Myo-2 peptide multimer.

The EL-32 application includes claims directed to pharmaceutical product approaches involving a microorganism transformed with a cell surface display vector operably linked to genes encoding myostatin and activin A proteins. The filing includes claims directed to potential use of the microorganism to preserve lean muscle mass in a human patient, including embodiments involving lactic acid bacteria such as Lactobacillus paracasei.

Targeting a Major Emerging Need in the GLP-1 Market

The company believes the rapid adoption of GLP-1 and related incretin-based obesity treatments, such as semaglutide and tirzepatide, may create an emerging opportunity for complementary approaches focused on preserving lean muscle mass during weight loss. While GLP-1 and next-generation obesity therapies have become widely recognized for their role in weight management, the company believes maintaining lean muscle mass during obesity-related weight loss may become an increasingly important area of product development and clinical focus.